{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:30:06Z","timestamp":1794508206418,"version":"4.9.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.autrev.2026.104090","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:55:42Z","timestamp":1779292542000},"page":"104090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chimeric antigen receptor-based cellular therapy in autoimmune diseases: A systematic review and meta-analysis of clinical, serological and safety outcomes"],"prefix":"10.1016","volume":"25","author":[{"given":"Hon Jen","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainsley Ryan Yan Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qai Ven","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen Hee","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2026.104090_bb0005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.autrev.2026.104090_bb0010","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104090_bb0015","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/LVT.0000000000000341","article-title":"Management of long-term complications from immunosuppression","volume":"30","author":"Russo","year":"2024","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.autrev.2026.104090_bb0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.abd.2023.05.005","article-title":"Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know","volume":"99","author":"Tavares","year":"2024","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.autrev.2026.104090_bb0025","doi-asserted-by":"crossref","first-page":"1447337","DOI":"10.3389\/fimmu.2024.1447337","article-title":"Autoimmune diseases refractory to corticosteroids and immunosuppressants","volume":"15","author":"Elkoshi","year":"2024","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104090_bb0030","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.autrev.2026.104090_bb0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.autrev.2026.104090_bb0040","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for Systemic Lupus Erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2026.104090_bb0045","first-page":"509","article-title":"iPSC-derived CAR-NK cells for systemic sclerosis. Nature reviews","volume":"21","author":"Webster","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2026.104090_bb0050","doi-asserted-by":"crossref","first-page":"1461102","DOI":"10.3389\/fimmu.2024.1461102","article-title":"CAR immunotherapy in autoimmune diseases: promises and challenges","volume":"15","author":"Yu","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104090_bb0055","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00210-025-04425-z","article-title":"CAR T cell therapy efficacy and safety in SLE: a systematic review and pooled analysis of 47 patients across 10 studies","volume":"399","author":"Sayed","year":"2026","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104090_bb0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","article-title":"Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review","volume":"45","author":"Kattamuri","year":"2025","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2026.104090_bb0065","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2026.104090_bb0070","doi-asserted-by":"crossref","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104090_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104090_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000616","article-title":"LLDAS (lupus low disease activity state) and\/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily mestizo population: data from the Almenara lupus cohort","volume":"9","author":"Ugarte-Gil","year":"2022","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104090_bb0085","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.1016\/j.autrev.2026.104090_bb0090","series-title":"Cochrane handbook for systematic reviews of interventions","volume":"4","author":"Chandler","year":"2019"},{"key":"10.1016\/j.autrev.2026.104090_bb0095","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.autrev.2026.104090_bb0100","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"Bmj"},{"issue":"7","key":"10.1016\/j.autrev.2026.104090_bb0105","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104090_bb0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.autrev.2026.104090_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.autrev.2026.104090_bb0120","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.ard.2025.06.2128","article-title":"BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis","volume":"84","author":"Hu","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"18","key":"10.1016\/j.autrev.2026.104090_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.autrev.2026.104090_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100749","article-title":"Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission","volume":"6","author":"Wang","year":"2025","journal-title":"Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104090_bb0135","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41422-025-01128-1","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus","volume":"35","author":"Yang","year":"2025","journal-title":"Cell Res"},{"issue":"23","key":"10.1016\/j.autrev.2026.104090_bb0140","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","article-title":"Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis","volume":"188","author":"Qin","year":"2025","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.autrev.2026.104090_bb0145","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2026.104090_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103489","article-title":"Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study","volume":"157","author":"Wang","year":"2025","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.autrev.2026.104090_bb0155","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood.2025028375","article-title":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","volume":"146","author":"M\u00fcller","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.autrev.2026.104090_bb0160","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41422-024-01068-2","article-title":"Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis","volume":"35","author":"Li","year":"2025","journal-title":"Cell Res"},{"issue":"2","key":"10.1016\/j.autrev.2026.104090_bb0165","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104090_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100704","article-title":"Anti-BCMA CAR-T cell therapy in relapsed\/refractory chronic inflammatory demyelinating polyneuropathy","volume":"6","author":"Dong","year":"2025","journal-title":"Med"},{"issue":"12","key":"10.1016\/j.autrev.2026.104090_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(25)00215-2","article-title":"Anti-BCMA CAR-T for the treatment of IgG4-related disease: clinical assessment and single-cell transcriptomic analysis","volume":"7","author":"Cai","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104090_bb0180","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104090_bb0185","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMc2403743","article-title":"Anti-CD19 CAR T cells in refractory immune thrombocytopenia of SLE","volume":"391","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104090_bb0190","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200479","article-title":"Anti-CD19 CAR T-cell therapy in advanced stiff-person syndrome and concomitant myasthenia gravis","volume":"12","author":"Ayzenberg","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.autrev.2026.104090_bb0195","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/s41375-025-02554-1","article-title":"Anti-CD19 CAR-T cell therapy for acquired hemophilia a","volume":"39","author":"Schultze-Florey","year":"2025","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.autrev.2026.104090_bb0200","article-title":"Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome","volume":"5","author":"Wickel","year":"2024","journal-title":"Cell Rep Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104090_bb0205","first-page":"2001","article-title":"Anti-CD19 chimeric antigen receptor T cell therapy achieved rapid and sustained remission in a patient with systemic lupus erythematosus-associated refractory immune thrombocytopenia","volume":"43","author":"Zhao","year":"2025","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104090_bb0210","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104090_bb0215","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104090_bb0220","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.autrev.2026.104090_bb0225","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1007\/s00415-024-12367-4","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"issue":"10437","key":"10.1016\/j.autrev.2026.104090_bb0230","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104090_bb0235","article-title":"Case report: remission of a patient with complex combination of autoimmune diseases by anti-CD19 CAR-T cell therapy","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104090_bb0240","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/ard-2024-226437","article-title":"CD-19 CAR-T cells for polyrefractory rheumatoid arthritis","volume":"84","author":"Lidar","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104090_bb0245","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1056\/NEJMc2508023","article-title":"CD19 CAR T-cell therapy in multidrug-resistant ulcerative colitis","volume":"393","author":"M\u00fcller","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104090_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100676","article-title":"CD19 CAR-T cell therapy in a pediatric patient with MDA5(+) dermatomyositis and rapidly progressive interstitial lung disease","volume":"6","author":"Par\u00eds-Mu\u00f1oz","year":"2025","journal-title":"Med"},{"issue":"7","key":"10.1016\/j.autrev.2026.104090_bb0255","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(25)00199-1","article-title":"CD19-targeted CAR T-cell therapy for treatment-refractory autoimmune neuropathies","volume":"24","author":"Motte","year":"2025","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104090_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"issue":"24","key":"10.1016\/j.autrev.2026.104090_bb0265","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with Antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.autrev.2026.104090_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100776","article-title":"Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis","volume":"6","author":"Hegelmaier","year":"2025","journal-title":"Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104090_bb0275","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/ard-2024-226017","article-title":"Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis","volume":"83","author":"Haghikia","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104090_bb0280","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.ard.2025.04.029","article-title":"Effective use of anti-CD19 chimeric antigen receptor T cells in a case of treatment-resistant granulomatosis with polyangiitis","volume":"84","author":"Uhlmann","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"10.1016\/j.autrev.2026.104090_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.autrev.2026.104090_bb0290","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1093\/rheumatology\/keaf190","article-title":"A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy-case report and literature review","volume":"64","author":"Haase","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2026.104090_bb0295","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S2213-2600(25)00159-6","article-title":"Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years","volume":"13","author":"Merkt","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.autrev.2026.104090_bb0300","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.ekir.2025.05.016","article-title":"Point-of-care anti-CD19-CAR T-cell therapy induces renal remission in refractory myeloperoxidase-antineutrophil cytoplasmic autoantibody-associated Vasculitis","volume":"10","author":"Schultze-Florey","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.autrev.2026.104090_bb0305","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2026.104090_bb0310","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"10.1016\/j.autrev.2026.104090_bb0315","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2403227121","article-title":"Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome","volume":"121","author":"Faissner","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.autrev.2026.104090_bb0320","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1093\/rheumatology\/keaf077","article-title":"Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis","volume":"64","author":"Albach","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2026.104090_bb0325","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104090_bb0330","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"10468","key":"10.1016\/j.autrev.2026.104090_bb0335","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/S0140-6736(24)02265-7","article-title":"Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells","volume":"404","author":"Hagen","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.autrev.2026.104090_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.autrev.2026.104090_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103692","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","volume":"24","author":"He","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2026.104090_bb0350","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s12015-025-10923-7","article-title":"Validation of BCMA-CD19 compound CAR-T therapy in SLE overlap syndrome: over 1.5-year follow-up","volume":"21","author":"Wang","year":"2025","journal-title":"Stem Cell Rev Rep"},{"issue":"11","key":"10.1016\/j.autrev.2026.104090_bb0355","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1038\/s41591-025-03899-x","article-title":"Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Wang","year":"2025","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.autrev.2026.104090_bb0360","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104090_bb0365","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.ard.2025.07.028","article-title":"Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus","volume":"84","author":"Fu","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104090_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104090_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2024.102137","article-title":"Outcomes with chimeric antigen receptor T-cell therapy in rheumatological disorders: a systematic review","volume":"87","author":"Zulfiqar","year":"2024","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.autrev.2026.104090_bb0380","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.omto.2019.08.002","article-title":"Parallel comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T cells for B cell non-Hodgkin’s lymphoma","volume":"15","author":"Ying","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.autrev.2026.104090_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1502712","article-title":"CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?","volume":"15","author":"Rangel-Pel\u00e1ez","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104090_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1392831","article-title":"Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis","volume":"15","author":"Han","year":"2024","journal-title":"Front Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104090_bb0395","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jcyt.2020.01.015","article-title":"The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor\u2013T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma","volume":"22","author":"Cao","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.autrev.2026.104090_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1178403","article-title":"A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells","volume":"14","author":"Fergusson","year":"2023","journal-title":"Front Immunol"},{"issue":"15","key":"10.1016\/j.autrev.2026.104090_bb0405","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of Obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104090_bb0410","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/10781552211073575","article-title":"Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma","volume":"28","author":"Davis","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"10.1016\/j.autrev.2026.104090_bb0415","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","article-title":"New insights into the role of antinuclear antibodies in systemic lupus erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104090_bb0420","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.rdc.2021.04.006","article-title":"B cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies","volume":"47","author":"Canny","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.autrev.2026.104090_bb0425","doi-asserted-by":"crossref","DOI":"10.1111\/imr.70058","article-title":"Human atypical B cells. An overview","volume":"334","author":"Sanz","year":"2025","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104090_bb0430","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104090_bb0435","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12967-023-04019-4","article-title":"Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy","volume":"21","author":"Li","year":"2023","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104090_bb0440","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010702","article-title":"Tailoring CAR surface density and dynamics to improve CAR-T cell therapy","volume":"13","author":"Hinckley-Boned","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.autrev.2026.104090_bb0445","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:43:32Z","timestamp":1785167012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":89,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1568997226001047"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104090","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor-based cellular therapy in autoimmune diseases: A systematic review and meta-analysis of clinical, serological and safety outcomes","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104090"}}